abs297.txt	stromal	cells	within	the	tumor	microenvironment	play	a	supportive	role	in	tumorgrowth		progression		and	treatment	resistance		therefore		these	nonmalignantcells	are	potential	therapeutic	targets		in	this	issue	of	the	jci		szot	et	al	devised	a	strategy	to	exploit	the	cell-surface	marker	tem8	(also	known	asantxr1)		which	is	expressed	by	cancer-associated	stromal	cells		as	a	zip	code	todeliver	an	antibody-drug	conjugate	(adc)	linked	to	the	potent	cancer-killing	drugmonomethyl	auristatin	e	(mmae)		in	preclinical	tumor	and	experimental	metastasismodels	of	multiple	cancer	types		tem8-adc	targeted	tem8-expressingcancer-associated	stromal	cells		which	processed	and	liberated	membrane-permeablemmae	and	released	this	drug	via	the	p-glycoprotein	(p-gp)	drug	transporter	released	mmae	killed	cancer	cells	through	a	bystander	mechanism	that	did	minimaldamage	to	the	stromal	cells	themselves		p-gp-expressing	tumor	cells	displayedmmae	resistance		suggesting	that	p-gp	expression	status	may	identify	patients	whomight	benefit	the	most	from	tem8-adc		this	strategy		termed	daarts	(drugactivation	and	release	through	stroma)		represents	an	elegant	example	of	howselective	expression	of	a	cell-surface	molecule	on	cancer-associated	stroma	canbe	exploited	to	facilitate	drug	delivery	and	shrink	solid	tumors	
